Glioblastoma is the most invasive form of brain tumor. Although temozolomide
chemotherapy has been shown to significantly improve survival in patients with GBM, this …

Highlights•Temozolomide resistance can be induced by glioblastoma cells.•Resistance to
temozolomide is caused by multiple mechanisms.•Different resistance pathways exist in …

Glioblastoma multiforme (GBM; WHO astrocytoma grade IV) is considered incurable owing
to its inherently profound resistance towards current standards of therapy. Considerable …

Temozolomide (TMZ) is a first-choice alkylating agent inducted as a gold standard therapy
for glioblastoma multiforme (GBM) and astrocytoma. A majority of patients do not respond to …

Abstract Purpose of Review Temozolomide is a first-line treatment for newly diagnosed
glioblastoma. In this review, we will examine the use of temozolomide in other contexts for …

Glioblastoma (GBM) is an aggressive and incurable tumor of the brain with limited treatment
options. Current first-line standard of care is the DNA alkylating agent temozolomide (TMZ) …

Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and has an
exceedingly low median overall survival of only 15 months. Current standard-of-care for …

Temozolomide (TMZ), an oral alkylating prodrug which delivers a methyl group to purine
bases of DNA (O6-guanine; N7-guanine and N3-adenine), is frequently used together with …

Glioblastoma multiforme is the most common aggressive adult primary tumour of the central
nervous system. Treatment includes surgery, radiotherapy and adjuvant temozolomide …

A glioblastoma (GBM) is one of the most aggressive, infiltrative, and treatment-resistant
malignancies of the central nervous system (CNS). The current standard of care for GBMs …